Welcome to our dedicated page for Airsculpt Technologies news (Ticker: AIRS), a resource for investors and traders seeking the latest updates and insights on Airsculpt Technologies stock.
AirSculpt Technologies Inc. (AIRS) delivers innovative body contouring solutions through its patented AirSculpt® technology, combining medical precision with minimally invasive techniques. This news hub provides investors and industry observers with essential updates on corporate developments, clinical advancements, and market positioning.
Access official press releases covering earnings reports, facility expansions, technology patents, and partnership announcements. Our curated collection enables efficient tracking of operational milestones in the competitive medical aesthetics sector.
Key coverage areas include regulatory filings, procedure innovation updates, executive leadership changes, and strategic growth initiatives. All content is sourced directly from company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined monitoring of AIRS's progress in advancing body contouring technologies and expanding its North American clinic network. Verify publication dates for the latest developments in this dynamic healthcare segment.
AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025. The company will release results before market open, followed by a conference call at 8:00 a.m. Eastern Time.
Investors can join the conference call via telephone by dialing 1-877-407-9716 (domestic) or 1-201-493-6779 (international) with conference ID 13753206. Alternatively, a live webcast will be available through the investor relations section of AirSculpt's website, with replay access for approximately 90 days.
AirSculpt Technologies (NASDAQ:AIRS) reported challenging fourth quarter and full year 2024 results, showing significant declines across key metrics. Q4 revenue dropped 17.7% to $39.2 million, with case volume declining 16.7% to 3,064 cases. The company posted a Q4 net loss of $5.0 million.
For full year 2024, revenue decreased 7.9% to $180.4 million, with case volume falling 6.0% to 14,036. Net loss widened to $8.3 million from $4.5 million in 2023, while Adjusted EBITDA declined to $20.7 million from $43.2 million.
The company has implemented a cost reduction program targeting $3 million in annual savings and has paused new center openings. With $8.2 million in cash and operating cash flow of $11.4 million for 2024, AirSculpt has secured additional covenant relief from lenders to support its transformation efforts.
AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has scheduled its fourth quarter 2024 financial results announcement for Friday, March 14, 2025, before market open.
The company will host a conference call at 8:30 a.m. Eastern Time on the same day. Investors can access the call through toll-free domestic (1-877-407-9716) or international (1-201-493-6779) numbers using conference ID 13751643. A live webcast will be available through the investor relations section of AirSculpt's website, with a replay accessible for approximately 90 days.
AirSculpt Technologies (NASDAQ: AIRS) has updated its fiscal year 2024 guidance, lowering expectations from previous projections. The company now anticipates revenues of approximately $180.0 million, down from the previous guidance of $183-189 million, and Adjusted EBITDA of approximately $20.5 million, reduced from the previous $23-28 million range.
New CEO Yogi Jashnani, who recently started his position, outlined plans to stabilize revenue and return to growth by implementing business process changes and enhancing technology usage. The company, which has performed over 70,000 procedures across 32 global centers, aims to leverage its proprietary technology and asset-light business model for long-term profitable growth.
AirSculpt Technologies (NASDAQ: AIRS), a premium body contouring procedures provider, has announced its participation in the upcoming ICR Conference 2025 at The Grande Lakes Orlando in Florida. The event will take place from January 13-14, 2025.
CEO Yogi Jashnani and CFO Dennis Dean will conduct investor meetings and deliver a presentation on January 14, 2025, at 10:00 a.m. EST. The presentation will be accessible via live webcast on the company's investor relations website, with the recording remaining available for 90 days.
AirSculpt Technologies (NASDAQ:AIRS) has appointed Yogi Jashnani as Chief Executive Officer and Board member, effective January 7, 2025. Jashnani succeeds Interim CEO Dennis Dean, who will continue as Chief Financial Officer. With over two decades of experience, Jashnani joins from Sky Zone where he served as Chief Revenue Officer.
Previously, as Chief Commercial Officer at Ideal Image, Jashnani drove growth through loyalty programs and new services. His experience includes executive roles at Advance Auto Parts, where he doubled eCommerce revenue, and Capital One Financial Services. The appointment aims to capitalize on AirSculpt's market position in premium body contouring procedures.
Jashnani's priorities will focus on accelerating same-center sales growth, enhancing operational efficiencies, and maximizing the potential of the AirSculpt method.
AirSculpt Technologies (NASDAQ: AIRS) has announced the opening of its new body contouring center in White Plains, NY, marking its 32nd location. The new facility features three operating rooms for simultaneous procedures and offers the AirSculpt+ skin tightening procedure. This expansion represents the company's second location in New York, responding to growing market demand. The AirSculpt+ procedure combines fat removal with Renuvion® technology, using helium gas and radiofrequency energy for skin tightening. Since 2012, over 60,000 AirSculpt procedures have been performed across their locations in the U.S., Canada, and the United Kingdom.
AirSculpt Technologies (NASDAQ:AIRS) reported Q3 2024 results with revenue of $42.5 million, representing a 9.1% decline from Q3 2023. The company posted a net loss of $6.0 million and Adjusted EBITDA of $4.7 million. Case volume decreased 4.3% to 3,277 cases. Despite challenges in the consumer environment, the company opened four new centers during the quarter. For the first nine months of 2024, revenue declined 4.8% to $141.2 million. The company affirmed its 2024 guidance with revenue expected between $183-189 million and Adjusted EBITDA between $23-28 million.
AirSculpt® Technologies, Inc. (NASDAQ: AIRS), a leader in premium body contouring procedures, has opened a new center in Birmingham, MI, increasing its total locations to 31. The center, located at 555 S. Old Woodward Avenue Suite 500, features two operating rooms for concurrent procedures and offers the popular AirSculpt®+ skin tightening procedure.
Dennis Dean, Interim CEO, expressed excitement about introducing AirSculpt's exclusive technology to Birmingham. The clinic is situated on the main strip, surrounded by upscale retail shops. AirSculpt®+ combines AirSculpt® fat removal with Renuvion® treatment, using helium gas and radiofrequency energy to tighten skin and improve laxity.
Since 2012, over 60,000 AirSculpt® cases have been performed across the company's locations in the U.S., Canada, and the United Kingdom.